Kymera to present KT-621 atopic dermatitis trial data at dermatology meeting

March 10, 2026 7:01 AM

Kymera Therapeutics Inc. (NASDAQ: KYMR) will present Phase 1b clinical trial data for its experimental drug KT-621 in atopic dermatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found